IRIS Accounts Production v24.3.2.46 11687196 director 1.1.24 31.12.24 31.12.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh116871962023-12-31116871962024-12-31116871962024-01-012024-12-31116871962022-12-31116871962023-01-012023-12-31116871962023-12-3111687196ns15:EnglandWales2024-01-012024-12-3111687196ns14:PoundSterling2024-01-012024-12-3111687196ns10:Director12024-01-012024-12-3111687196ns10:PrivateLimitedCompanyLtd2024-01-012024-12-3111687196ns10:SmallEntities2024-01-012024-12-3111687196ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-3111687196ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-3111687196ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-3111687196ns10:FullAccounts2024-01-012024-12-3111687196ns10:RegisteredOffice2024-01-012024-12-3111687196ns5:CurrentFinancialInstruments2024-12-3111687196ns5:CurrentFinancialInstruments2023-12-3111687196ns5:ShareCapital2024-12-3111687196ns5:ShareCapital2023-12-3111687196ns5:RetainedEarningsAccumulatedLosses2024-12-3111687196ns5:RetainedEarningsAccumulatedLosses2023-12-3111687196ns5:ComputerEquipment2024-01-012024-12-3111687196ns5:ComputerEquipment2023-12-3111687196ns5:ComputerEquipment2024-12-3111687196ns5:ComputerEquipment2023-12-3111687196ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-3111687196ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-31116871961ns10:Director12023-12-31116871961ns10:Director12022-12-31116871961ns10:Director12024-01-012024-12-31116871961ns10:Director12023-01-012023-12-31116871961ns10:Director12024-12-31116871961ns10:Director12023-12-31
REGISTERED NUMBER: 11687196 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

MEADGATE PHARMA SOLUTIONS LIMITED

MEADGATE PHARMA SOLUTIONS LIMITED (REGISTERED NUMBER: 11687196)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


MEADGATE PHARMA SOLUTIONS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2024







DIRECTOR: Z M Daya





REGISTERED OFFICE: Chargrove House
Shurdington Road
Cheltenham
Gloucestershire
GL51 4GA





REGISTERED NUMBER: 11687196 (England and Wales)





ACCOUNTANTS: Randall & Payne LLP
Chartered Accountants
Chargrove House
Shurdington Road
Cheltenham
Gloucestershire
GL51 4GA

MEADGATE PHARMA SOLUTIONS LIMITED (REGISTERED NUMBER: 11687196)

BALANCE SHEET
31 DECEMBER 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 266 753

CURRENT ASSETS
Debtors 5 138,646 242,271
Cash at bank 25,350 3,494
163,996 245,765
CREDITORS
Amounts falling due within one year 6 40,552 47,141
NET CURRENT ASSETS 123,444 198,624
TOTAL ASSETS LESS CURRENT
LIABILITIES

123,710

199,377

PROVISIONS FOR LIABILITIES 67 188
NET ASSETS 123,643 199,189

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 123,543 199,089
SHAREHOLDERS' FUNDS 123,643 199,189

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 25 March 2025 and were signed by:



Z M Daya - Director


MEADGATE PHARMA SOLUTIONS LIMITED (REGISTERED NUMBER: 11687196)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024

1. STATUTORY INFORMATION

Meadgate Pharma Solutions Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Turnover is measured ar the fair value of the consideration received or receivable, excluding discount, rebates, value added tax and other sales tax. Revenue is recognised once the work has been completed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Computer equipment - 33% on cost

Financial instruments
Financial Instrument are classified by the directors as basic or advanced following the conditions in FRS 102 Section 11.Basic financial instrument are recognised at amortised cost using the effective interest method.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

MEADGATE PHARMA SOLUTIONS LIMITED (REGISTERED NUMBER: 11687196)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

2. ACCOUNTING POLICIES - continued

Going concern
The director has considered the risks and issues concerning the company and it's activities and no material uncertainties that may cast significant doubt about the company's ability to continue as a going concern has been identified by the director.

Provisions
Provisions are recognised only where a present obligation exists as a result of a past transaction or event at or prior to the balance sheet date. In addition, a provision is only recognised where the amounts involved can be reliably estimated. Where material, provisions are calculated on a discounted basis.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. TANGIBLE FIXED ASSETS
Computer
equipment
£   
COST
At 1 January 2024 5,860
Disposals (3,347 )
At 31 December 2024 2,513
DEPRECIATION
At 1 January 2024 5,107
Charge for year 487
Eliminated on disposal (3,347 )
At 31 December 2024 2,247
NET BOOK VALUE
At 31 December 2024 266
At 31 December 2023 753

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors 7,046 30,662
Directors' loan accounts 69,700 46,496
Prepayments and accrued income 61,900 165,113
138,646 242,271

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Corporation Tax 20,337 37,234
VAT 20,215 9,907
40,552 47,141

MEADGATE PHARMA SOLUTIONS LIMITED (REGISTERED NUMBER: 11687196)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2024

7. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 31 December 2024 and 31 December 2023:

2024 2023
£    £   
Z M Daya
Balance outstanding at start of year 46,497 76,741
Amounts advanced 212,641 135,279
Amounts repaid (189,438 ) (165,523 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 69,700 46,497

Interest is being charged on the loan at the HMRC approved rate and there are no set repayment terms.